Trial Profile
An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Onatasertib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms TORCH
- Sponsors Antengene Corporation
- 06 Jul 2023 Status changed from active, no longer recruiting to discontinued. Based on the adjustment of clinical research and development strategy, sponsor decided to terminate the study.
- 19 Apr 2023 Results presented at the 114th Annual Meeting of the American Association for Cancer Research
- 17 Apr 2023 According to an Antengene Corporation media release, data from this study were presented at the American Association for Cancer Research Annual Meeting 2023 Meetings (AACR 2023).